Maria Dominguez, MD
Child & Adolescent Psychiatry · San Antonio, TXNPI 1891738449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 404 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,352 and has fallen 63.0% since, to $500 in 2025. Among child & adolescent psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 404 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$743
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$658
- Takeda Pharmaceuticals U.S.A., Inc.$597
- Johnson & Johnson$410
- Otsuka America Pharmaceutical, Inc.$405
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,668100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 122 | $1,403 |
| Sunovion Pharmaceuticals Inc. | 38 | $743 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $658 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $597 |
| Johnson & Johnson | 17 | $410 |
| Otsuka America Pharmaceutical, Inc. | 22 | $405 |
| Neos Therapeutics, LP | 14 | $287 |
| Ironshore Pharmaceuticals Inc. | 17 | $272 |
| Corium, LLC | 15 | $266 |
| Teva Pharmaceuticals USA, Inc. | 10 | $219 |
| Avanir Pharmaceuticals, Inc. | 10 | $174 |
| Supernus Pharmaceuticals, Inc. | 7 | $143 |
| Alkermes, Inc. | 6 | $141 |
| Vanda Pharmaceuticals Inc. | 6 | $140 |
| Tris Pharma Inc | 6 | $101 |
| EMD Serono, Inc. | 5 | $96 |
| Shire North American Group Inc | 5 | $79 |
| Noven Therapeutics, LLC | 4 | $78 |
| Idorsia Pharmaceuticals US Inc | 4 | $70 |
| Adlon Therapeutics L.p. | 5 | $69 |
| Merck | 3 | $59 |
| Almatica Pharma LLC | 2 | $37 |
| Collegium Pharmaceutical, Inc. | 2 | $37 |
| Lundbeck LLC | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Vertical Pharmaceuticals, LLC | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Neuronetics, Inc. | 1 | $24 |
| Tempus AI, Inc | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
How this compares
$6,692 in reported general payments places this provider in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LybalviOlanzapine/Samidorphan Malate | 12 | $17,676 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| SeroquelQuetiapine Fumarate | 26 | $11,400 |
| Bupropion XlBupropion Hcl | 98 | $2,610 |
| Clozapine | 24 | $2,580 |
| Lisdexamfetamine Dimesylate | 13 | $2,379 |
| Aripiprazole | 89 | $2,376 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $2,123 |
| Clonazepam | 223 | $2,057 |
| Fluvoxamine Maleate | 28 | $2,031 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 54 | $1,942 |
| Oxcarbazepine | 40 | $1,844 |
| Duloxetine Hcl | 78 | $1,765 |
| Divalproex Sodium | 13 | $1,474 |
| Buspirone Hcl | 79 | $1,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Lybalvi | $141 | $17,67612 claims |
| AbbVieVraylar | $1,403 | $16,00011 claims |
| Almatica Pharma LLCSertraline Hcl | $37 | $57569 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 301 child & adolescent psychiatry providers in Texas.
Other child & adolescent psychiatry in San Antonio
- Steven PliszkaSan Antonio$59K
- Mary Garcia HolguinSan Antonio$24K
- Amber MansoorSan Antonio$6K
- Andrew MartinSan Antonio$6K
- Thomas DemoorSan Antonio$5K
- Vanessa VelaSan Antonio$3K
- Marguerite HoganSan Antonio$3K
- Grace Salinas GarciaSan Antonio$2K
- Hector SamaniegoSan Antonio$2K
- Alain KaticBellaire$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.